BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Target Hit|| Long (1Y)
Bank of America Merrill Lynch maintains buy on Lupin
The launch of Niacin (Vitamin B) with 100-day semi-exclusivity is a positive. Lupin remains top pick in Indian pharma space. Company has highest earnings growth among peers. Target Rs 1120.